Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 7/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.32 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 8/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314874 | 0.84 | TEAD1 (0.36) | TEAD1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20314855 | 0.73 | BTK (0.34) | TEAD1JAK3 | |
| SCHEMBL23544836 | 0.73 | JAK3 (0.41) | TEAD1JAK3 | |
| SCHEMBL20314873 | 0.73 | JAK3 (0.41) | TEAD1JAK3 | |
| SCHEMBL23735765 | 0.73 | TET3 (0.34) | TEAD1TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20334399 | 0.73 | GPR183 (0.54) | TEAD1GPR183TET3KMT2AFBXL19 | |
| SCHEMBL20314921 | 0.72 | TEAD1 (0.34) | TEAD1KMT2AJAK3 | |
| SCHEMBL19353212 | 0.71 | DPP4 (0.40) | DPP4DPP8DPP9TEAD1JAK3 | |
| SCHEMBL20334389 | 0.71 | DPP4 (0.36) | DPP4TEAD1JAK3 | |
| SCHEMBL23544835 | 0.71 | JAK3 (0.35) | TEAD1KMT2AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DPP4 3354/4885DPP8 2325/4885DPP9 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.